Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

BenzingaNov 26 22:37 ET

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

Zacks Nov 26 10:05 ET

JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsNov 26 06:31 ET · Ratings

Promising Outlook for Intellia Therapeutics' Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest

TipRanksNov 26 06:17 ET

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

MT NewswiresNov 25 13:45 ET

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

MT NewswiresNov 25 11:02 ET